Skip to main content
Sign In

Welcome to the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine on the Anschutz Medical Campus in Aurora, Colorado.

Barbara Davis Center Banner Image
 

AAT: Alpha1-Antitrypsin


 

The effects of open label alpha1-antitrypsin on the progression of type 1 diabetes in subjects with detectable c-peptide

Principal Investigator: Peter Gottlieb, MD

COMIRB # 09-0667

The AAT Study

The drug Alpha-1 Antitrypsin (AAT, Aralast NP), which is being tested in this clinical trial, is an anti-inflammatory drug that affects the cells that are thought to be involved in the development of type 1 diabetes. This trial is designed to investigate the effect of intravenous AAT on preserving beta cell function and to determine if AAT will help slow the progression of type 1 diabetes.

Who can participate?

• Diagnosis of Type 1 Diabetes Mellitus based on ADA Criteria for fewer than 5 years but more than 100 days.
• 6-46 years of age.
• Positive for antibodies to insulin
• Agree to intensive management of diabetes with an HgbA1c goal of < 7.0%

What will happen in this study?

• You will be assessed for general health and diabetes care
• Eligible subjects will be treated once a week for 8 weeks (8 total treatments) with study drug administered by infusion.
• Typically, these infusions will last under 1 hour. Infusions will take place at the outpatient CTRC. All subjects will receive study drug, this is an open label trial.

Who should I call with questions or to schedule an appointment?

Lisa Meyers: 303-724-6893 or Lisa.Meyers@ucdenver.edu  

Dominic DiDomenico: 303-724-5687 or Dominic.DiDomenico@ucdenver.edu